Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk-Stratified Analysis in 540 Patients

Leukemia

Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-matched analysis

Leuk Lymphoma

Huang YH, Liu FT, Wan CL, Wang ZJ, Liu YQ, Cao HY, Huang SM, Tan KW, Ge SS, Wang M, Liu MJ, Wang ZH, Lyu XY, Dai HP, Li Z, Xue SL

doi: 10.1080/10428194.2025.2566317

Leukemia

Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia

Am J Hematol

Jones MK, Sanchez J, Connor M, Julian K, Rezac R, Marciano K, Tobin J, Bosma G, Abbott D, Anttila K, Sohalski C, Belachew A, McMahon C, Kent A, Amaya M, Angelos MG, Schwartz M, Gutman JA, Pollyea DA

doi: 10.1002/ajh.70231

Leukemia

IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy

Haematologica

Hoff FW, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Zeidner JF, Olin RL, Smith CC, Schiller GJ, Curran EK, Handa SV, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Byrd JC, Madanat YF

doi: 10.3324/haematol.2025.288743

Leukemia

Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint

Leukemia

Castagnetti F, Breccia M, Abruzzese E, Bassan R, Binotto G, Bonifacio M, Caocci G, Capodanno I, Cavazzini F, Cimino G, Fazi P, Gozzini A, Iurlo A, Janssen JJWM, Lunghi M, Marasca R, Martino B, Messina M, Muriano F, Paoloni F, Piciocchi A, Rosti G, Russo Rossi A, Saglio G, Sica S, Soverini S, Tafuri A, Vallisa D, Westerweel PE, Pane F

doi: 10.1038/s41375-025-02796-z

Leukemia

Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING study

Haematologica

Wang ES, Montesinos P, Minden MD, Sibai H, Lee JH, Heuser M, Naoe T, Chou WC, Laribi K, Esteve J, Altman JK, Havelange V, Watson AM, Fumagalli M, Patkowska E, Hill JE, Gill SC, Pandya BJ, Chen C, Hasabou N

doi: 10.3324/haematol.2026.301112

Leukemia

Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial

Br J Haematol

Palmieri R, Piciocchi A, Soddu S, Frigeni M, Borlenghi E, Fracchiolla N, Martelli MP, Audisio E, Cignetti A, Gianfaldoni G, Vetro C, di Rienzo N, Esposito D, Di Veroli A, Selleri C, Gigli F, Curti A, Mulè A, Califano C, Bigliardi S, Breccia M, Fozza C, Bocchia M, Lico A, Simonetti F, Pierdomenico E, Marchetti M, Cerroni I, Buccisano F, Del Principe MI, Maurillo L, Paterno G, Fazi P, Vignetti M, Rossi G, Rambaldi A, Venditti A

doi: 10.1111/bjh.70752

Leukemia

Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor

Haematologica

Short NJ, Loghavi S, Yilmaz M, Karrar O, Kim K, Dinardo CD, Kadia TM, Maroun M, Borthakur G, Issa GC, Jabbour J, Oran B, Shpall EJ, Popat U, Patel KP, Routbort M, Konopleva M, Ravandi F, Kantarjian H, Daver N

doi: 10.3324/haematol.2025.288553

Leukemia

Heart failure in patients with acute myeloid leukemia (AML) treated with anthracycline agents during remission induction therapy: a systematic review and meta-analysis

Leukemia

Geels J, van Rhenen A, Gradowska P, Asselbergs FW, Linschoten M

doi: 10.1038/s41375-025-02753-w

Myelodysplastic syndromes

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database

Blood Cancer J

Bewersdorf JP, Kewan T, Lanino L, Wei W, Rudra Gupta T, Stempel JM, Al Ali NH, DeZern AE, Sekeres MA, Uy GL, Urrutia S, Carraway HE, Desai P, Griffiths EA, Stein EM, Brunner AM, McMahon C, Shallis RM, Zeidner JF, Savona MR, Hawkins H, Chandhok NS, Logothetis CN, Bidikian A, Getz TM, Roboz GJ, Rolles B, Wang ES, Harris AC, Amaya ML, Ball S, Grenet J, Xie Z, Madanat YF, Abaza Y, Badar T, Campos J, Haferlach T, Maciejewski JP, Sallman D, Enjeti A, Al-Rabi K, Halahleh K, Hiwase D, Diez-Campelo M, Valcarcel D, Haferlach C, Pleyer L, Kotsianidis I, Pappa V, Santini V, Consagra A, Al-Kali A, Ogawa S, Nannya Y, Stahl M, Della Porta MG, Komrokji RS, Zeidan AM

doi: 10.1038/s41408-026-01543-6

Related content

Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-matched analysis

Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia

IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy

Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint

Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING study

Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial

Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor

Heart failure in patients with acute myeloid leukemia (AML) treated with anthracycline agents during remission induction therapy: a systematic review and meta-analysis

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database